Focusing since 1967 on the isolation of various biochemicals produced by the human body as part of the body’s possible defense against cancer, the penny stock of Burzynski Research Institute, Inc. (BZYR) has exploded on the scene thanks to the efforts of CEO and President Stanislaw R. Burzynski, M.D., Ph.D. After notification that the U.S. Food and Drug Administration lifted its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections, shares of BZYR stock begun to trade and are putting on a good show thus far. Although only around 25 million shares issued and outstanding do not belong to the founder who is determined to treat of various forms of brain tumors, the large jump upwards has made this little biotech burz-worthy.
Our Next Pick Is Coming Soon!
Click HERE To Make Sure You Don’t Miss Any Of Our Hot Penny Stock Alerts!
BZYR Stock Quote
Market Cap: 13.14M
Last: 0.10 ▲ +0.06 (+150%)
Dollar Volume: $44,984
14-Day RSI: 67.11%
1st Resistance Point: 0.137
1st Support Level: 0.076
52Wk High: 0.15
52Wk Low: 0.03
Conducting research for decades already from the Burzynski Research Institute in Houston, TX, Dr. Burzynski actually began to research cancer in 1967 and, in 2004 was granted orphan drug designation by the FDA for the Company’s Antineoplastons (A10 & AS2-1 Antineoplaston) which targeted patients with brain stem glioma. Four years later, in 2008, the FDA granted the Company’s request for orphan drug designation for Antineoplastons (A10 and AS2-1 Antineoplaston) for the treatment of gliomas.
Burzynski Research Institute is no spring chicken when it comes to biotechnology companies looking for the safest, most effective cure to the most deadly disease the U.S. has – cancer. Clinical studies regarding Antineoplastons by Dr. Burzynski date back well past 1994 with the largest group of test subjects suffering from primary brain tumors.
Everything looked to be headed towards a treatment that worked until, in a letter dated June 25, 2012, Burzynski Research Institute informed the FDA of a serious adverse event which may have been related to the administration of Antineoplastons. The following month, the FDA placed a partial clinical hold for enrollment of new pediatric patients under single patient protocols or in any of the active Phase II or Phase III studies under IND 43,742 because, according to the FDA, insufficient information had been submitted by the Company to allow the FDA to determine whether the potential patient benefit justifies the potential risks of treatment use, and that the potential risks are not unreasonable in the context of the disease or condition to be treated.
Hence today’s news that research and possibly clinical studies can recommence is a huge catalyst moving forward for a company which, not only has been staying afloat by the founder’s funding, but also had just $152,903 in total liabilities despite $3,963,418 and $6,047,676 having been expended during the years ended February 28, 2013 and 2012, respectively, in research and development costs.
What’s reveling is that BZYR already has a stock chart available despite today being the biggest volume trading session since November, 2011 when shares rushed to as high as 0.51 after a week long run. Today’s breaking announcement of the FDA’s partial lifting which will could soon lead to the potential clinical trial for Antineoplastons A10/AS2-1 Injections has rightfully landed BZYR stock on the map.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About BZYR Stock
Burzynski Research Institute, Inc. is a development stage, biotechnology company engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name “Antineoplastons.”
Click here to view the SEC filings for BZYR.
Click here to view the website for Burzynski Research Institute.
Issued and Outstanding: 131,448,444
Stanislaw R. Burzynski, M.D., Ph.D.: 106,368,278
Last 5 Trading Sessions:
Today’s volume surge is sure to attract some of the “buy and hold” traders that can see BZYR no longer being a penny stock after having a closer look at it. Considering how small the float is on BZYR stock, it’s a good thing this news came out now in June and not January or we would be looking at a $1 or $2 in front of the 0.10 that it’s sitting at right now.
[gravityform id=”6″ name=”Post” title=”false”]Share